Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition, Collaboration Agreements and Other (Details Narrative)

v3.23.2
Revenue Recognition, Collaboration Agreements and Other (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2022
Apr. 08, 2022
Apr. 08, 2022
Nov. 19, 2020
Dec. 12, 2019
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2023
Jun. 30, 2022
Revenue             $ 1,063   $ 1,096 $ 1,063
BioNTech Agreement [Member]                      
Fees received   $ 2,750                  
Revenue recognized $ 688   $ 2,750       $ 688        
Revenue             $ 375        
CFF Agreement [Member]                      
Grants receivable           3,600       3,600  
Additional milestone payment           4,500       4,500  
CFF Agreement [Member] | Accrued Liabilities [Member]                      
Other Liabilities $ 88         $ 0       $ 0  
CFF Agreement [Member] | Cystic Fibrosis Foundation [Member]                      
Therapeutics development award       $ 4,200              
Proceeds from award       $ 484              
Additional milestone payment                 $ 321    
Genentech Feasibility Study Agreement [Member] | Genentech [Member]                      
Revenue         $ 33            
Agreement description         Genentech paid the Company a total of $100 for the development of three molecules, or $33 per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement.            
Aggregate revenue         $ 100